MISSION Appoints Paul Wallace as Chief Business Officer

16/03/2015 - 2 minutes

Mission Therapeutics, a company focused on the discovery and development of modulators of the deubiquitylating (DUB) enzyme family for the treatment of cancer and other diseases, appointed Paul Wallace as Chief Business Officer. The appointment highlights the scope and productivity of Mission’s drug discovery platform.

Dr. Wallace joins Mission to formulate future business strategy at a time when the company’s pipeline has matured to the point where strategic options such as development partnerships are ready to be explored. Having worked in business development roles within drug discovery companies for nearly 20 years, Dr. Wallace was most recently Executive Vice President and Head of Business Development at Medivir AB, where he was also a member of the Executive Management Team responsible for strategic and operational leadership, R&D portfolio management and investment planning. During this period, he played a key role: not only did the company seal 25 partnership deals under his leadership, it also brought 8 products into clinical development, 2 drugs were launched and Medivir transitioned into a profitable pharmaceutical firm.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

Support Us

Become a Member